CRANBURY, N.J., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will present a corporate overview at the Goldman Sachs US Emerging / SMID Cap Growth Conference in New York, NY on Thursday, November 19, 2015 at 1:50 p.m. ET.
A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus' lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and other lysosomal storage disorders.
CONTACT: Investors/Media: Amicus Therapeutics Sara Pellegrino Director, Investor Relations firstname.lastname@example.org (609) 662-5044 Media: Pure Communications Dan Budwick email@example.com (973) 271-6085
Source:Amicus Therapeutics, Inc.